Recombinant human growth hormone therapy in malnourished dialysis patients: a randomized controlled study
| Autor: | Rafael Selgas, Abelardo Aguilera, JL Miguel, S Burgues, Pedro Iglesias, Díez Jj, J Martinez-Ara, A Gomez-Pan, Fernández-Reyes Mj |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Adult
Male medicine.medical_specialty Anabolism medicine.medical_treatment Nutritional Status Pilot Projects Gastroenterology Peritoneal dialysis Blood Urea Nitrogen Peritoneal Dialysis Continuous Ambulatory Renal Dialysis Internal medicine Medicine Humans Insulin-Like Growth Factor I Blood urea nitrogen Dialysis Aged business.industry Continuous ambulatory peritoneal dialysis Body Weight Transferrin Middle Aged medicine.disease Endocrinology Nephrology Growth Hormone Kidney Failure Chronic Female Hemodialysis medicine.symptom business Weight gain Kidney disease Follow-Up Studies |
| Zdroj: | American journal of kidney diseases : the official journal of the National Kidney Foundation. 32(3) |
| ISSN: | 1523-6838 |
| Popis: | Recombinant human growth hormone (rhGH; Saizen, Serono, Spain) has been recently used as an anabolic agent in several catabolic states, including malnourished chronic dialysis patients. However, up-to-date, comparative studies with control groups of dialysis patients have not been reported. The aim of the present study was to assess the effects of rhGH on nutritional status in a group of malnourished adult chronic dialysis patients undergoing both continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis (HD). The patients were randomly assigned to the control group (nine patients; 6 women, 3 men; mean age, 58.3 +/- 5.6 years; seven undergoing CAPD, two undergoing HD) or the rhGH group (eight patients; three women, five men; mean age, 63.9 +/- 3.1 years; four undergoing CAPD, four undergoing HD). Both groups were similar at baseline. All patients were given dietary prescriptions (35 kcal/kg/d and 1 g protein/kg ideal body weight/d) during 4 weeks. In the rhGH group, rhGH was administered at 0.2 IU/kg/d subcutaneously (SC) during this period. Anthropometric and analytic parameters were assessed before (0 weeks) therapy and at 2 and 4 weeks after starting therapy. The rhGH group showed an increase of 1.238 kg in body weight from 64.3 +/- 4.3 (mean +/- standard error of the mean [SEM]) to 65.6 +/- 4.9 kg (P < 0.05). Serum insulin-like growth factor type 1 (IGF-1) concentrations increased from 216.6 +/- 42.5 to 581.2 +/- 171.5 ng/mL (4 weeks; P < 0.01) and transferrin levels increased from 271.2 +/- 16.3 to 314.5 +/- 21.2 mg/dL (4 weeks; P < 0.05). A significant reduction in blood urea nitrogen (BUN) level was observed (62.1 +/- 1.8 v 46.8 +/- 3.8 mg/dL; 4 weeks; P < 0.05). Mean daily protein intake, determined by individual dietary survey, at 0 and 4 weeks, remained constant in both groups. In conclusion, weight gain and IGF-1 and transferrin level increases and BUN level decreases, despite the constant oral intake, suggest that short-term rhGH administration is associated with an anabolic reaction in malnourished dialysis patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|